Natixis Advisors L.P. Acquires 101,237 Shares of Anika Therapeutics Inc (NASDAQ:ANIK)

Share on StockTwits

Natixis Advisors L.P. grew its holdings in shares of Anika Therapeutics Inc (NASDAQ:ANIK) by 179.7% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 157,559 shares of the biotechnology company’s stock after purchasing an additional 101,237 shares during the quarter. Natixis Advisors L.P. owned approximately 1.14% of Anika Therapeutics worth $6,400,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in ANIK. C M Bidwell & Associates Ltd. bought a new stake in Anika Therapeutics in the second quarter worth about $44,000. BNP Paribas Arbitrage SA increased its stake in shares of Anika Therapeutics by 356.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 2,891 shares of the biotechnology company’s stock worth $87,000 after purchasing an additional 2,257 shares during the last quarter. SG Americas Securities LLC increased its stake in shares of Anika Therapeutics by 99.8% during the 1st quarter. SG Americas Securities LLC now owns 6,477 shares of the biotechnology company’s stock worth $196,000 after purchasing an additional 3,235 shares during the last quarter. Aperio Group LLC bought a new stake in shares of Anika Therapeutics in the 2nd quarter worth approximately $205,000. Finally, HL Financial Services LLC raised its holdings in shares of Anika Therapeutics by 7.3% in the 1st quarter. HL Financial Services LLC now owns 6,988 shares of the biotechnology company’s stock worth $211,000 after purchasing an additional 475 shares during the period. 93.74% of the stock is owned by hedge funds and other institutional investors.

ANIK has been the topic of several research analyst reports. First Analysis upgraded Anika Therapeutics from a “neutral” rating to a “strong-buy” rating and upped their price objective for the company from $37.00 to $54.00 in a research note on Thursday, July 25th. Zacks Investment Research downgraded Anika Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, July 26th. BidaskClub lowered Anika Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, September 4th. TheStreet raised Anika Therapeutics from a “c” rating to a “b-” rating in a research report on Friday, July 26th. Finally, ValuEngine upgraded Anika Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, July 3rd. Three analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. Anika Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $46.00.

In other news, Director Joseph L. Bower sold 1,994 shares of the stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $55.57, for a total value of $110,806.58. Following the sale, the director now directly owns 43,010 shares of the company’s stock, valued at $2,390,065.70. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Raymond J. Land sold 3,000 shares of the stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $55.44, for a total transaction of $166,320.00. Following the completion of the sale, the director now directly owns 11,992 shares in the company, valued at $664,836.48. The disclosure for this sale can be found here. Over the last quarter, insiders sold 14,192 shares of company stock valued at $800,681. 3.67% of the stock is owned by company insiders.

Anika Therapeutics stock traded down $0.33 during mid-day trading on Wednesday, reaching $55.28. The company’s stock had a trading volume of 36,848 shares, compared to its average volume of 147,561. Anika Therapeutics Inc has a 12-month low of $29.01 and a 12-month high of $58.93. The company has a market capitalization of $759.44 million, a P/E ratio of 30.04, a PEG ratio of 3.15 and a beta of 1.08. The company has a debt-to-equity ratio of 0.09, a quick ratio of 16.07 and a current ratio of 18.28. The firm’s fifty day moving average price is $55.19 and its two-hundred day moving average price is $40.62.

Anika Therapeutics (NASDAQ:ANIK) last issued its earnings results on Wednesday, July 24th. The biotechnology company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.42 by $0.25. The business had revenue of $30.42 million for the quarter, compared to analysts’ expectations of $27.41 million. Anika Therapeutics had a net margin of 26.87% and a return on equity of 11.27%. The business’s revenue for the quarter was down .4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.68 EPS. On average, research analysts predict that Anika Therapeutics Inc will post 1.75 EPS for the current fiscal year.

Anika Therapeutics Profile

Anika Therapeutics, Inc, together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology.

See Also: What is Elliott Wave theory?

Want to see what other hedge funds are holding ANIK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anika Therapeutics Inc (NASDAQ:ANIK).

Institutional Ownership by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.